Full Text View
Tabular View
Study Results
Related Studies
To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia
This study has been completed.
Study NCT00271817   Information provided by Merck

First Received on January 3, 2006.   Last Updated on April 14, 2010   History of Changes
Results First Received: February 13, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Hypercholesterolemia
Interventions: Drug: Comparator: ezetimibe/simvastatin + niacin (ER)
Drug: Comparator: Placebo to ezetimibe/simvastatin
Drug: Comparator: niacin (ER) tablet
Drug: Comparator: ezetimibe (+) simvastatin
Drug: Comparator: Placebo to Niacin (ER)
Drug: Comparator: ezetimibe/simvastatin and niacin (ER)
Drug: Comparator: ezetimibe and simvastatin
Drug: Comparator: Placebo to niacin (ER)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Niacin (Part 1): Niacin titrated to 2000 mg taken orally once daily for 24 weeks. During the first 12 weeks of the study, patients randomized to the niacin containing arms started taking niacin 500 mg and had their niacin dose increased 500 mg every 4 weeks to 2000 mg. Patients in this treatment group were ramdomly reassigned for Part 2 of the study to one of two treatment groups- two-thirds of the patients enrolled in the niacin treatment group were randomly assigned to receive ezetimibe/simvastatin + niacin (ER) and the other one-third were randomly assigned to receive ezetimibe/simvastatin alone.
Ezetimibe/Simvastatin

(Part 1): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.

(Part 2): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.
Ezetimibe/Simvastatin + Niacin

(Part 1): Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg as noted above) taken orally once daily for 24 weeks.

(Part 2): Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.

Participant Flow for 2 periods

 Period 1:   Part 1
    Niacin     Ezetimibe/Simvastatin     Ezetimibe/Simvastatin + Niacin  
STARTED     272     272     676  
COMPLETED     166 [1]   213 [2]   391 [3]
NOT COMPLETED     106     59     285  
Adverse Event                 68                 25                 156  
Lost to Follow-up                 6                 8                 24  
Protocol Violation                 5                 4                 7  
Patient Moved                 3                 1                 5  
Withdrawal by Subject                 23                 17                 45  
LDL < 50 mg/dL                 1                 4                 48  
[1] 6 patients who completed Part 1 did not continue to Part 2; 1 patient never received drug in Part 2
[2] 1 patient who completed Part 1 did not continue to Part 2
[3] 11 patients who completed Part 1 did not continue to Part 2

Period 2:   Part 2
    Niacin     Ezetimibe/Simvastatin     Ezetimibe/Simvastatin + Niacin  
STARTED     0 [1]   266 [2]   485 [3]
COMPLETED     0     234     401  
NOT COMPLETED     0     32     84  
Adverse Event                 0                 17                 33  
Lack of Efficacy                 0                 1                 6  
Lost to Follow-up                 0                 6                 18  
Protocol Violation                 0                 3                 5  
Patient Moved                 0                 0                 5  
Withdrawal by Subject                 0                 2                 13  
LDL < 50 mg/dL                 0                 3                 4  
[1] Patients completing the niacin group in Part 1, were re-allocated to one of the two arms in Part 2
[2] Includes 54 patients re-allocated from the niacin group in Part 1
[3] Includes 105 patients re-allocated from the niacin group in Part 1



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Niacin (Part 1): Niacin titrated to 2000 mg taken orally once daily for 24 weeks. During the first 12 weeks of the study, patients randomized to the niacin containing arms started taking niacin 500 mg and had their niacin dose increased 500 mg every 4 weeks to 2000 mg.
Ezetimibe/Simvastatin

(Part 1): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.

(Part 2): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.
Ezetimibe/Simvastatin + Niacin

(Part 1): Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg as noted above) taken orally once daily for 24 weeks.

(Part 2): Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.

Baseline Measures
    Niacin     Ezetimibe/Simvastatin     Ezetimibe/Simvastatin + Niacin     Total  
Number of Participants  
[units: participants]
 		  272     272     676     1220  
Age  
[units: years]
Mean ± Standard Deviation 		  56.4  ± 10.6     57.5  ± 10.3     56.9  ± 10.9     56.9  ± 10.7  
Gender  
[units: participants]
 		       
Female     136     120     352     608  
Male     136     152     324     612  
Race/Ethnicity, Customized  
[units: participants]
 		       
Asian     11     4     11     26  
Black     13     17     38     68  
Hispanic     14     11     49     74  
Other     3     0     2     5  
White     231     240     576     1047  
Body Mass Index  
[units: Participants]
 		       
<25 kg/m2     48     39     135     222  
25 to <30 kg/m2     110     119     252     481  
30 to <40 kg/m2     97     94     251     442  
≥ 40 kg/m2     16     19     34     69  
No BMI Data     1     1     4     6  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)   [ Time Frame: Baseline and 24 Weeks ]
  Show Outcome Measure 1

2.  Primary:   Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)   [ Time Frame: Baseline and 24 weeks ]
  Show Outcome Measure 2

3.  Secondary:   Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)   [ Time Frame: Baseline and 24 weeks ]
  Show Outcome Measure 3

4.  Secondary:   Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)   [ Time Frame: Baseline and 24 weeks ]
  Show Outcome Measure 4

5.  Secondary:   Percent Change From Baseline in Triglycerides (TG)   [ Time Frame: baseline and 24 Weeks ]
  Show Outcome Measure 5

6.  Secondary:   Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)   [ Time Frame: Baseline and 64 weeks ]
  Show Outcome Measure 6

7.  Secondary:   Percent Change From Baseline in Triglycerides (TG)   [ Time Frame: Baseline and 64 weeks ]
  Show Outcome Measure 7

8.  Secondary:   Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)   [ Time Frame: Baseline and 64 weeks ]
  Show Outcome Measure 8

9.  Secondary:   Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)   [ Time Frame: Baseline and 64 weeks ]
  Show Outcome Measure 9

10.  Secondary:   Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)   [ Time Frame: Baseline and 24 weeks ]
  Show Outcome Measure 10


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Part 1 population is all patients enrolled in Part 1 of the study. Part 2 is those patients who received either niacin, ezetimibe/simvastatin, or ezetimibe/simvastatin + niacin during Part 1 until they finished the study at week 64 or discontinued.  


Results Point of Contact:  
Name/Title: Executive Vice President, Clinical and Quantitative Sciences
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372


Publications:
Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72.


Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier: NCT00271817     History of Changes
Other Study ID Numbers: 2005_091, MK0653A-091
Study First Received: January 3, 2006
Results First Received: February 13, 2009
Last Updated: April 14, 2010
Health Authority: United States: Food and Drug Administration





Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services